Solvonis Therapeutics plc (LON: SVNS)

Market Cap	4.36M
Revenue (ttm)	347.00K
Net Income (ttm)	-2.62M
Shares Out	2.30B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,118,396
Average Volume	16,473,512
Open	0.208
Previous Close	0.210
Day's Range	0.190 - 0.208
52-Week Range	0.100 - 1.407
Beta	1.84
RSI	49.93
Earnings Date	Apr 25, 2025

About Solvonis Therapeutics

Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous poly...

• Industry: Plastics Materials, Synthetic Resins, and Nonvulcanizable Elastomers
• Founded: 2017
• Employees: 7
• Stock Exchange: London Stock Exchange
• Ticker Symbol: SVNS

Financial Performance

In 2023, Solvonis Therapeutics's revenue was 587,000, an increase of 8.30% compared to the previous year's 542,000. Losses were -3.12 million, 15.3% more than in 2022.